Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD7+ T-ALL/LBL”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Very early researchStudy completedNCT05902845
What this trial is testing

RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL

Who this might be right for
NeoplasmsHematologic NeoplasmsHematologic Diseases
Xiaoyu Zhu 4
Early research (Phase 1)Not Yet RecruitingNCT07623681
What this trial is testing

Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

Who this might be right for
CD7+ T-ALL/LBL
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 12
Early research (Phase 1)Study completedNCT04572308
What this trial is testing

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

Who this might be right for
T-cell Acute Lymphoblastic Leukemia/Lymphoma
Hebei Senlang Biotechnology Inc., Ltd. 20
Not applicableUnknownNCT04620655
What this trial is testing

RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

Who this might be right for
T Acute Lymphoblastic LeukemiaT-lymphoblastic Lymphoma
Min Xiang 24
Very early researchWithdrawnNCT04860817
What this trial is testing

Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL

Who this might be right for
T-cell Acute Lymphoblastic LeukemiaT-lymphoblastic Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Not applicableStudy completedNCT04938115
What this trial is testing

Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

Who this might be right for
Leukemia, T Cell
Hebei Senlang Biotechnology Inc., Ltd. 50
Early research (Phase 1)Study completedNCT04984356
What this trial is testing

Of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Who this might be right for
T-cell Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Wugen, Inc. 28
Very early researchStudy completedNCT05907603
What this trial is testing

Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)

Who this might be right for
NeoplasmsHematologic NeoplasmsHematologic Diseases
Kai Lin Xu，MD 8
Very early researchNot Yet RecruitingNCT07476027
What this trial is testing

Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL

Who this might be right for
T Lymphoblastic LymphomaT Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 10
Early research (Phase 1)UnknownNCT05398614
What this trial is testing

SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

Who this might be right for
T-ALLLymphoma, T-Cell
Hebei Senlang Biotechnology Inc., Ltd. 18
Early research (Phase 1)Looking for participantsNCT06136364
What this trial is testing

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

Who this might be right for
T-lymphoblastic LymphomaT-ALL
Hebei Senlang Biotechnology Inc., Ltd. 9
Testing effectiveness (Phase 2)Study completedNCT05454241
What this trial is testing

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Who this might be right for
Hematological Malignancies
Institute of Hematology & Blood Diseases Hospital, China 14
Not applicableLooking for participantsNCT05626400
What this trial is testing

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Who this might be right for
T-cell Acute Lymphoblastic Leukemia/Lymphoma
Hebei Senlang Biotechnology Inc., Ltd. 100
Early research (Phase 1)Looking for participantsNCT07109518
What this trial is testing

UCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Who this might be right for
Acute Myeloid Leukemia (AML)T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 12
Early research (Phase 1)Looking for participantsNCT07280494
What this trial is testing

To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

Who this might be right for
CD7+ T-ALL/LBL
Peking University People's Hospital 18
Very early researchStudy completedNCT05716113
What this trial is testing

CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL

Who this might be right for
NeoplasmsHematologic NeoplasmsNeoplasms by Site+1 more
He Huang 20
Not applicableEnrolling By InvitationNCT05509855
What this trial is testing

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

Who this might be right for
T-cell Acute Lymphoblastic LeukemiaT-cell Lymphoblastic Lymphoma
Wugen, Inc. 44
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07244380
What this trial is testing

Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.

Who this might be right for
T Lymphoblastic Leukemia/Lymphoma
Hebei Senlang Biotechnology Inc., Ltd. 38
Testing effectiveness (Phase 2)Looking for participantsNCT07153068
What this trial is testing

SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Who this might be right for
T Lymphoblastic Leukemia/LymphomaAcute Myeloid Leukemia (AML)
Institute of Hematology & Blood Diseases Hospital, China 12